Analyst Reco. COMPASS Pathways plc

Equities

CMPS

US20451W1018

Real-time Estimate Cboe BZX Other stock markets 02:20:54 2024-05-03 pm EDT			5-day change	1st Jan Change
8.65 ^USD	+4.85%		+9.95%	-0.23%

Apr. 29	Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	CI
Apr. 18	Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18	MT
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18	MT
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02	MT
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02	MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01	MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01	MT
Morgan Stanley Initiates COMPASS Pathways at Overweight With $30 Price Target	Apr. 01	MT
Deutsche Bank Initiates Coverage on COMPASS Pathways With Buy Rating, $16 Price Target	Dec. 12	MT
Canaccord Genuity Cuts Price Target on COMPASS Pathways to $50 From $60, Maintains Buy Rating	23-08-22	MT
Citigroup Adjusts Price Target on COMPASS Pathways to $19 From $45, Maintains Buy Rating	23-03-01	MT
EF Hutton Initiates COMPASS Pathways at Buy With $38 Price Target	22-12-16	MT
Oppenheimer Adjusts COMPASS Pathways Price Target to $33 From $55, Maintains Outperform Rating	22-12-09	MT
Berenberg Resumes COMPASS Pathways at Buy With $33 Price Target	22-11-21	MT
Loop Capital Initiates COMPASS Pathways at Buy With $34 Price Target	22-11-01	MT
Oppenheimer Adjusts COMPASS Pathways Price Target to $55 From $65, Maintains Outperform Rating	22-10-13	MT
Citigroup Trims Price Target on COMPASS Pathways to $46 From $49, Reiterates Buy Rating	22-08-05	MT
Berenberg Bank Suspends Coverage of 25 Companies in Consumer Discretionary, Healthcare, Industrial Tech, and Software Sectors	22-07-01	MT
Berenberg European Conference	21-12-05	FA
HC Wainwright Adjusts COMPASS Pathways' Price Target to $120 from $100, Keeps Buy Rating	21-11-22	MT
Berenberg Bank Adjusts COMPASS Pathways PT to $84 From $50, Maintains Buy Rating	21-11-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. COMPASS Pathways plc

Equities

CMPS

US20451W1018

Analyst Reco.

Filters